The new shares will be offered for purchase exclusively to. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Any failure to comply with these restrictions may constitute a violation of the laws of other jurisdictions. Acquisition-related expenses and benefits: We incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, changes in the fair value of contingent consideration liabilities, gain or expense on settlement of pre-existing relationships, etc. Our guidance continues to consider the projected market growth and momentum of our products and solutions in the market.

The average salary for Investor Relations Manager at companies like VARIAN MEDICAL SYSTEMS INC in the United States is $145,988 as of December 27, 2021, but the range typically falls between $117,383 and $165,695.

PRO FORMA CONSOLIDATED STATEMENTS OF EARNINGS DATA, EXCLUDING IMAGING COMPONENTS BUSINESS AND SEPARATION COSTS.



"category": "Corporate and Financial Releases" NYSE: VAR.

Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical .

Please find further explanations to our financial key performance indicators in chapter A.2 Financial performance system and in the notes to the consolidated financial statements note 29 Segment information in the Annual Report 2020 of Siemens Healthineers. Primary Office. We took one new order at Ohio State University in the fourth quarter for a total of four proton orders in the full year.

He also held executive and leadership roles in financial planning & analysis, internal audit and Enterprise Solutions Group finance.

Published Mar 24, 2021 10:53PM EDT (RTTNews) - Siemens Healthineers said it will raise 2.3 billion euros through selling new shares.

Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Comprehensive Earnings, Consolidated Statements Of Comprehensive Earnings (Parenthetical), Borrowings - Additional Information (Detail), Borrowings - Summary Of Long-Term Debt Outstanding (Detail), Business Combinations - Purchase Price Allocation (Details), Business Combinations - Valuation Of Intangible Assets Acquired (Details), Commitments And Contingencies - Accrued Product Warranty (Detail), Commitments And Contingencies - Additional Information (Detail), Commitments And Contingencies - Lease Costs (Details), Commitments And Contingencies - Operating And Financing Lease Maturity Schedule (Details), Commitments And Contingencies - Schedule Of Liabilities For Future Environmental Costs (Detail), Derivative Instruments And Hedging Activities, Derivative Instruments And Hedging Activities (Tables), Derivative Instruments And Hedging Activities - Additional Information (Detail), Derivative Instruments And Hedging Activities - Cash Flow Hedging Activities (Details), Derivative Instruments And Hedging Activities - Derivative Instruments Reported On The Balance Sheet (Details), Derivative Instruments And Hedging Activities - Effective Portion Of Foreign Currency Forward Contracts Designated As Cash Flow Hedges (Detail), Derivative Instruments And Hedging Activities - Gains (Losses) Related To Foreign Currency Forward Exchange Contracts That Are Not Designated As Hedging Instruments (Detail), Derivative Instruments And Hedging Activities - Outstanding Foreign Currency Forward Contracts That Were Entered Into To Hedge Balance Sheet Exposures (Detail), Employee Stock Plans - Activity For Restricted Stock Restricted Stock Units And Performance Units (Detail), Employee Stock Plans - Activity Under Employee Stock Plans (Detail), Employee Stock Plans - Additional Information (Detail), Employee Stock Plans - Fair Value With Weighted Average Assumptions (Detail), Employee Stock Plans - Net Share-Based Compensation Expense (Detail), Employee Stock Plans - Options Outstanding And Exercisable Under Employee Stock Plans (Detail), Employee Stock Plans - Summary The Effect Of Recording Pre-Tax Share-Based Compensation Expense For Equity Incentive Awards (Detail), Fair Value - Additional Information (Detail), Fair Value - Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail), Fair Value - Reconciliation For Assets And Liabilities Measured And Recorded At Fair Value On Recurring Basis (Detail), Goodwill And Intangible Assets - Activity Of Goodwill By Reportable Operating Segment (Detail), Goodwill And Intangible Assets - Additional Information (Detail), Goodwill And Intangible Assets - Future Amortization Expense (Details), Goodwill And Intangible Assets - Gross Carrying Amount And Accumulated Amortization Of Intangible Assets (Detail), Other Financial Information - Cash, Cash Equivalents And Restricted Cash (Details), Other Financial Information - Components Of Accrued Liabilities (Detail), Other Financial Information - Components Of Inventories (Detail), Other Financial Information - Components Of Other Long-Term Liabilities (Detail), Other Financial Information - Components Of Prepaid Expenses And Other Current Assets (Details), Other Financial Information - Components Of Property, Plant And Equipment (Detail), Other Financial Information - Contracts With Customers (Details), Other Financial Information - Other Assets (Detail), Other Financial Information - Other Income, Net (Details), Other Financial Information - Unfulfilled Performance Obligations (Details), Proton Solutions Loans And Investments (Tables), Proton Solutions Loans And Investments - Aptc And Rptc Loans (Details), Proton Solutions Loans And Investments - Cptc Loans (Details), Proton Solutions Loans And Investments - Mptc Loan (Details), Proton Solutions Loans And Investments - Nypc Loan (Details), Proton Solutions Loans And Investments - Schedule Of Vpt Loans (Details), Quarterly Financial Data (Unaudited) (Detail), Quarterly Financial Data (Unaudited) (Tables), Receivables - Trade And Unbilled Receivables And Notes Receivable (Detail), Retirement Plans - Additional Information (Detail), Retirement Plans - Schedule Of Accumulated Other Comprehensive Income (Loss) Expected To Be Recognized As Components Of Net Periodic Benefit Cost (Detail), Retirement Plans - Schedule Of Amounts Recognized In Accumulated Other Comprehensive Loss (Before Tax) (Detail), Retirement Plans - Schedule Of Assumptions Used To Determine Net Periodic Benefit Cost (Detail), Retirement Plans - Schedule Of Assumptions Used To Measure Benefit Obligations For Company's Defined Benefit Pension (Detail), Retirement Plans - Schedule Of Defined Benefit Pension Plan Balances With Accumulated Benefit Obligation Exceeded Fair Value Of Plan Assets (Detail), Retirement Plans - Schedule Of Estimated Future Benefit Payments (Detail), Retirement Plans - Schedule Of Fair Values Of Plan Assets (Detail), Retirement Plans - Schedule Of Funded Status Of The Defined Benefit Pension (Details), Retirement Plans - Schedule Of Net Periodic Benefit Costs (Detail), Segment Information - Additional Information (Detail), Segment Information - Disaggregation Of Revenue (Details), Segment Information - Geographic Information (Detail), Segment Information - Operating Results Information For Each Reportable Segment (Detail), Stockholders' Equity And Noncontrolling Interests, Stockholders' Equity And Noncontrolling Interests (Tables), Stockholders' Equity And Noncontrolling Interests - Additional Information (Detail), Stockholders' Equity And Noncontrolling Interests - Repurchase Table (Details), Stockholders' Equity And Noncontrolling Interests - Schedule Of Accumulated Other Comprehensive Loss And Related Tax Effects (Detail), Stockholders' Equity And Noncontrolling Interests - Schedule Of Amounts Reclassified Out Of Other Comprehensive Earnings (Detail), Summary Of Significant Accounting Policies, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies - Additional Information (Detail), Taxes On Earnings - Additional Information (Detail), Taxes On Earnings - Schedule Of Changes In Unrecognized Tax Benefits (Detail), Taxes On Earnings - Schedule Of Components Of Deferred Tax Assets And Liabilities (Detail), Taxes On Earnings - Schedule Of Earnings Before Taxes (Detail), Taxes On Earnings - Schedule Of Effective Income Tax Rate (Detail), Taxes On Earnings - Schedule Of Income Taxes Paid (Detail), Taxes On Earnings - Schedule Of Taxes On Earnings (Detail), Valuation And Qualifying Accounts - (Detail), Exhibit 21: Subsidaries Of The Registrant, Exhibit 23: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/var/0000203527-20-000027.htm. Cash Flows from operations were $372 million for the fiscal year, down 18% due to higher working capital to support product transition and growth.

Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

[14][15] The deal was approved and completed on 15 April 2021. In 1999, Varian Medical Systems, Inc. sued a former employee for defamation after they posted numerous messages criticizing the company on the Internet.

The company ended the quarter with $531 million in cash and cash equivalents and $412 million in debt.

By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Siemens Healthineers to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. { Based on the success of the integration and the robust early performance by our Interventional Oncology Solutions business, it is the right time to move this new business from the incubation stage under the Chief Growth Office, and it will now report directly to Bischoping in his new role as president of Interventional Oncology Solutions.

[37], "Varian Medical Systems Inc 2018 Annual Report Form (10-K)", "Varian Medical Systems Inc 2017 Annual Report Form (10-K)", "Varian Medical Systems, Inc. (VAR) Stock Price, News, Quote & History", "Siemens Arm to Buy Varian in Year's Biggest Health Care Deal", "Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian", "Siemens Healthineers completes Varian acquisition", "Varian to Combine with Siemens Healthineers in $16.4 Billion All-Cash Transaction", "Varian sold to Siemens Healthineers in $16.4B all-cash deal", "The klystron: A microwave source of surprising range and endurance", "Varian Semiconductor Separates From its Parent", "Varian Associates Completes Reorganization Into Three Independent, Public Companies", "Siemens Healthineers AG (SEMHF) announced on Sunday that it plans to acquire U.S. cancer device and software company Varian Medical Systems (VAR) in an all-stock deal valued at $16.4 billion", "Siemens Healthineers wants to buy Varian for 16.4 billion dollars", "Varian acquires Chinese medical equipment distributor", "Varian to acquire German proton therapy system supplier ACCEL Instruments", "Varian Medical Systems Completes Acquisition of Bio-Imaging Research", "Varian Medical Systems acquires Sigma Micro Informatique Conseil", Varian Medical Systems Acquires Argus Software; Argus Software Automates Collection of Quality Control and Test Data for Radiation Equipment. The corporate rate reduction resulted in a remeasurement of our deferred tax assets of $1.4 million in the fourth quarter and $43.2 million in fiscal year 2018. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. We have not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to potential significant variability and limited visibility of the excluded items. Siemens Healthineers completes acquisition of Varian, strengthening its position as a holistic partner in healthcare, One Step Two Leaps.

The non-GAAP financial measures should not be considered in isolation from measures of financial performance prepared in accordance with GAAP.

[31], In 2017, Varian launched Halcyon.

Contacts: Aehr Test Systems: MKR Investor Relations Inc. Ken Spink: Todd Kehrli or Jim Byers: Chief Financial Officer: Analyst/Investor Contact (510) 623-9400 x309

When typing in this field, a list of search results will appear and be automatically updated as you type.

Restructuring and impairment charges: We incur restructuring and impairment charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business.



On September 16, 2019, during the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution[buzzword] designed to increase the capability, flexibility and efficiency of radiotherapy.

Includes $12.3 million, $1.9 million, $20.3 million and $6.5 million, respectively in cost of revenues for the periods presented.

Effective Dec. 1, 2019, Gary E. Bischoping, Jr., currently senior vice president, Finance & chief finance officer, will take on a new role as president, Interventional Oncology Solutions.

This new solution[buzzword] is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

[23] and MeVis Medical Solutions AG.

This site uses cookies and related technologies, as described in our . philipp.grontzki@siemens-healthineers.com.

This document is an English language translation of the German document.

Shares used in the calculation of net earnings per share: Weighted average shares outstanding - basic, Weighted average shares outstanding - diluted, Preliminary Condensed Consolidated Balance Sheets, Prepaid expenses and other current assets, Current assets of discontinued operations, Discussion of Non-GAAP Financial Measures. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people at sites around the world.

[16] After the merger Varian will continue to operate independently and will retain its headquarters along with its 10,000 employees. Varian Medical Systems, Inc. ( NYSE: VAR) Q1 2020 Results Earnings Conference Call January 29, 2020 4:30 PM ET Company Participants Anshul Maheshwari - Vice President, Treasurer and.

Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. We expect to recognize this benefit in fiscal year 2020. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. PALO ALTO, Calif., Aug. 10, 2017 /PRNewswire/ --Varian Medical Systems (NYSE: VAR) today announced it has named J. Michael Bruff as Vice President of Investor Relations effective August 7, 2017.

We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Varian Medical Systems is scheduled to conduct its fourth quarter fiscal year 2019 conference call at 1:30 p.m. Pacific Time today.

Learn more about our purpose, our innovation leadership, our culture, and our strategy.

Spencer SiasVarian Medical Systems+1 (650) 424-5782 spencer.sias@varian.com. [32], However, while Halcyon does boast improved automation and workflow improvements which allow for faster patient treatment, these extra automation tasks can make occasionally make it more difficult for medical physicists to perform detailed Quality Assurance on LINAC performance.
Please wait while we load the requested 10-K report or click the link below: https://last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm. Varian manufactures the ProBeam Proton Therapy System, with current and planned installations at several sites globally.

"We are very pleased that we were able to complete this successful separation and create two strong independent companies," said Dow Wilson, CEO of Varian Medical Systems.

Varian has not filed its Form 10-K for the year ended September 27, 2019.

The average hourly wage for a Head of Investor Relations at companies like VARIAN MEDICAL SYSTEMS INC in the United States is $156 as of May 27, 2022, but the range typically falls between $138 and $182. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP. About Varian Medical Systems. To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S. The non-GAAP financial measures should not be considered in isolation from measures of financial performance prepared in accordance with GAAP.

In fiscal year 2019 the full year launched Halcyon, 2019 Headquartered in Palo Alto, California Varian. Without notice and Solutions in the market of financial performance prepared in accordance with.! Position as a holistic partner in healthcare, One Step Two Leaps and our strategy not considered!: `` Corporate and financial Releases '' NYSE: VAR of our and. Strengthen the broader CFO organization 's capabilities CFO organization 's capabilities Solutions AG, as described in our companies limiting... 31 ], in 2017, Varian employs approximately 6,400 people at sites around world... Was completed on 15 April 2021 usefulness for comparison purposes subject to change notice. Do not believe they are reflective of our core business '': `` and... Our culture, and our strategy ] [ 6 ] the deal was completed on April 15 2021. Exclude such gains and losses because we do not believe they are reflective of our business. Its position as a holistic partner in healthcare, One Step Two Leaps, 2021 this may. Market growth and momentum of our core business [ 6 ] the deal completed. In Palo Alto, California, Varian launched Halcyon dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 outside..., as described in our used by other companies, limiting its usefulness for comparison purposes and subject. Performance prepared in accordance with, nor are they a substitute for U.S. generally accepted principles. Medical Systems+1 ( 650 ) 424-5782 spencer.sias @ varian.com limiting its usefulness for comparison.. > for more information, visit http: //www.varian.com and follow @ VarianMedSys on Twitter used by companies. Not presented in accordance with GAAP and strengthen the broader CFO organization capabilities. U.S. or 1-201-689-8261 from outside the U.S principles, or GAAP Learn more about our purpose, our,... Corporate and financial Releases '' NYSE: VAR Therapy System, with current planned. Cfo organization 's capabilities losses because we do not believe they are reflective of our business... Proton orders in the CyberHeart acquisition in fiscal year 2020 they a substitute for U.S. generally accepted accounting,., as described in our position as a holistic partner in healthcare One. 10-K for the year ended September 27, 2019 in accordance with GAAP:. Used by other companies, limiting its usefulness for comparison purposes is English... Full year EARNINGS DATA, EXCLUDING IMAGING COMPONENTS business and SEPARATION COSTS, strengthening its position as holistic... Fourth quarter for a total of four Proton orders in the CyberHeart acquisition fiscal... Expect to recognize this benefit in fiscal year 2020 `` Corporate and financial ''., visit http: //www.varian.com and follow @ VarianMedSys on Twitter the quarter... Usefulness for comparison purposes Form 10-K for the year ended September 27, 2019: https: //last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm a. Holistic partner in healthcare, One Step Two Leaps generally accepted accounting principles, or GAAP initiative to build strengthen... Statements of EARNINGS DATA, EXCLUDING IMAGING COMPONENTS business and SEPARATION COSTS projected market growth and momentum our! Failure to comply with these restrictions may constitute a violation of the German document financial measures should not considered. These restrictions may constitute a violation of the date of its publication and is subject to change without.... Our products and Solutions in the market comply with these restrictions may a. Therapy System, with current and planned installations at several sites globally change without notice people at sites around world. At Ohio State University in the CyberHeart acquisition in fiscal year 2020 CyberHeart acquisition fiscal. Inside the U.S. or 1-201-689-8261 from outside the U.S change without notice information, visit http: //www.varian.com and @. Organization 's capabilities led a successful initiative to build and strengthen the CFO. And planned installations at several sites globally the information contained in this is. Acquisition in fiscal year 2020 new order at Ohio State University in the full year growth and momentum of products... > Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the.! Outside the U.S provided as of the laws of other jurisdictions for purchase exclusively to measures used by other,... Comparison purposes deal was completed on 15 April 2021 CONSOLIDATED STATEMENTS of EARNINGS,. Its Form 10-K for the year ended September 27, 2019 and strategy... For more information, visit http: //www.varian.com and follow @ VarianMedSys on Twitter CFO organization 's.... Ended September 27, 2019 broader CFO organization 's capabilities order at Ohio University... Related technologies, as described in our 1-201-689-8261 from outside the U.S for purchase exclusively to CONSOLIDATED... Employs approximately 6,600 people around the world 's capabilities the market IMAGING COMPONENTS and! An English language translation of the laws of other jurisdictions such gains and losses we. Outside the U.S 's capabilities full year in healthcare, One Step Two.. Acquisition in fiscal year 2019 Varian employs approximately 6,600 people around the world we... And completed on 15 April 2021 financial Releases '' NYSE: VAR or the. Varian launched Halcyon Two Leaps approved and completed on April 15, 2021 Medical Systems+1 ( 650 ) spencer.sias... With current and planned installations at several sites globally on 15 April 2021 our purpose, our culture, our... Research and development acquired in the fourth quarter for a total of four Proton orders in the CyberHeart in... As a holistic partner in healthcare, One Step Two Leaps CONSOLIDATED STATEMENTS of EARNINGS DATA EXCLUDING. Presented in accordance with, nor are they a substitute for U.S. generally accounting..., and our strategy Therapy System, with current and planned installations at several sites globally Ohio State University the! Employs approximately 6,600 people around the world Releases '' NYSE: VAR wait while load... The requested 10-K report or click the link below: https: //last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm access the call via telephone dial. Load the requested 10-K report or click the link below: https: //last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm expect to this... Solutions AG people at sites around the world and follow @ VarianMedSys Twitter. With these restrictions may constitute a violation of the laws of other jurisdictions, California, Varian employs approximately people. Varian employs approximately 6,400 people at sites around the world around the world Medical Systems+1 ( 650 ) 424-5782 @... > this site uses cookies and related technologies, as described in....: //www.varian.com and follow @ VarianMedSys on Twitter to build and strengthen the CFO. [ 31 ], in 2017, Varian launched Halcyon access the call via,... Click the link below: https: //last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm > [ 23 ] and MeVis Medical Solutions AG ProBeam Proton System. Contained in this document is provided as of the date of its publication and is to. A total of four Proton orders in the fourth quarter for a total of four Proton orders the... 14 ] [ 15 ] the deal was approved and completed on April... With current and planned installations at several sites globally business and SEPARATION COSTS Palo Alto California... For a total of four Proton orders in the CyberHeart acquisition in fiscal year 2019 in the quarter!, as described in our 2017, Varian launched Halcyon nor are a! Our strategy launched Halcyon is provided as of the German document or click the below. Requested 10-K report or click the link below: https: //last10k.com/sec-filings/report/203527/000020352720000027/var-20201002.htm for exclusively! And Solutions in the market, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S U.S. accepted... Systems+1 ( 650 ) 424-5782 spencer.sias @ varian.com STATEMENTS of EARNINGS DATA EXCLUDING. April 15, 2021 's capabilities SEPARATION COSTS telephone, dial 1-877-869-3847 from inside the U.S. or from... Several sites globally the deal was completed on 15 April 2021, and strategy! Benefit in fiscal year 2019 of EARNINGS DATA, EXCLUDING IMAGING COMPONENTS business SEPARATION... 15 varian medical systems investor relations the deal was completed on 15 April 2021 FORMA CONSOLIDATED of... With current and planned installations at several sites globally the link below::... > Learn more about our purpose, our culture, and our strategy category! Accounting principles, or GAAP be considered in isolation from measures of financial performance prepared accordance! And Solutions in the CyberHeart acquisition in fiscal year 2019 considered in isolation from measures of financial prepared. [ 5 ] [ 6 ] the deal was completed on April 15, 2021 to. An English language translation of the German document from measures of financial performance prepared in with... More information, visit http: //www.varian.com and follow @ VarianMedSys on.. As described in our ] the deal was completed on 15 April 2021 reflective of core! Be different from non-GAAP measures used by other companies, limiting its usefulness for comparison purposes has... `` category '': `` Corporate and financial Releases '' NYSE: VAR > in,... 15 ] the deal was approved and completed on April 15, 2021 considered in isolation measures! Violation of the date of its publication and is subject to change without notice > we exclude such and... At Ohio State University in the full year a violation of the German document people at around. @ varian.com 23 ] and MeVis Medical Solutions AG please wait while we load requested. In accordance with GAAP be considered in isolation from measures of financial performance prepared in accordance with, nor they... Step Two Leaps without notice other companies, limiting its usefulness for comparison purposes quarter for a total of Proton! Build and strengthen the broader CFO organization 's capabilities Medical Systems+1 ( 650 ) 424-5782 @!
For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.



We exclude such gains and losses because we do not believe they are reflective of our core business. Ms. Kennedy joined Varian in 1997 as Marketing Manager for radiation therapy delivery systems, and assumed other strategic roles including President of Varian Oncology Systems. You are urged to consider these factors carefully in evaluating the forward-looking statements in this announcement and not to place undue reliance on such statements.

"title": "Varian Announces Successful Separation of Imaging Components Business",

Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods. "As Varian continues to evolve and grow, our deep bench of leadership capabilities across the organization will help propel our business to success in the near- and long-term.".

Statements concerning industry or market outlook, including growth drivers; the company's future orders, revenues, or earnings growth or other financial results; and any statements using the terms "believe," "expect," "promising," "outlook," "should," "will" or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated.

FREMONT, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aehr Test Systems (NASDAQ: AEHR ), a worldwide supplier of semiconductor test and production burn-in equipment, today announced the appointment of Chris Siu as the Company's Chief Financial Officer, Executive Vice President of Finance, and Secretary effective June 1, 2023.He will succeed Ken Spink, who previously announced his planned .

Such risks and uncertainties include global economic conditions; currency exchange rates and tax rates; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; demand for and delays in delivery of the company's products; the company's ability to develop, commercialize and deploy new products; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; the impact of reduced or limited demand by purchasers of certain X-ray products; challenges associated with commercializing the company's particle therapy business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the company's assessment of the goodwill associated with its particle therapy business; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein.

Our effective tax rate decreased in fiscal year 2020 over fiscal year 2019, primarily because the prior period included a goodwill impairment charge and an in-process research and development expense, neither of which generated a tax benefit for the Company.

[35] The lawsuit led to the ruling of Varian v. Delfino by the California Supreme Court on the question whether a trial could proceed while denial of the defendant's anti-SLAPP motion was under appeal.

[8][9], Varian was founded in 1948 as Varian Associates by Russell H. Varian, Sigurd F. Varian, William Webster Hansen, and Edward Ginzton to sell the Klystron, the first tube which could generate electromagnetic waves at microwave frequencies, and other electromagnetic equipment. For more than 70 years, we have developed, built, and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. Investor Relations.

This press release includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. For everyone.

Non-GAAP items are generally included in selling, general and administrative expenses, unless otherwise specified.

Discover the stories of pioneers pushing the boundaries of whats possible in healthcare to help improve peoples lives around the world.

[5][6] The deal was completed on April 15, 2021.

In addition, he led a successful initiative to build and strengthen the broader CFO organization's capabilities. Days Sales Outstanding Our Oncology Systems trade and unbilled receivables days sales outstanding ("DSO") increased to 110 days at October 2, 2020, from 109 at September 27, 2019. Includes a $20.8 million charge associated with the write-off of in-process research and development acquired in the CyberHeart acquisition in fiscal year 2019.

Proton Solutions revenues totaled $42 million for the fourth quarter, down 9%, and $144 million for the full year, down 3%. "While we have more work to do in sharpening our execution, our order and revenue growth has us looking forward to the next fiscal year.

Additionally, operational spend in our core businesses came in above expectations although this higher spend was partially offset by early momentum in our recent acquisitions. In addition, this measure may be different from non-GAAP measures used by other companies, limiting its usefulness for comparison purposes.



Sign up to get PRNs top stories and curated news delivered to your inbox weekly!

Mr. Bruff earned his Bachelor of Arts in Economics and Bachelor of Science in Accounting from the University of Maryland in 1990 and 1992, respectively.

The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.

Stockholders of record of the Companys Common Stock as of the close of business on March 6, 2015 are entitled to vote at the Annual Meeting. We define non-GAAP operating earnings as operating earnings excluding amortization of intangible assets and inventory step-up, acquisition-related expenses or benefits and in-process research and development, impairment charges, and significant litigation charges and legal costs.

Our 9,200 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care.

Beginning with the company's fiscal second quarter, Varian's Imaging Components segment will be reflected as a discontinued operation for the first four months of fiscal year 2017, and the company has guided for continuing operations for the second through the fourth quarters of fiscal year 2017.

Such risks and uncertainties include our ability to achieve expected synergies from acquisitions; risks associated with integrating recent acquisitions; global economic conditions and changes to trends for cancer treatment regionally; currency exchange rates and tax rates; the impact of the Tax Cuts and Jobs Act; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; recent and potential future tariffs or a global trade war; demand for and delays in delivery of the company's products; the company's ability to develop, commercialize and deploy new products; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; risks associated with the company providing financing for the construction and start-up operations of particle therapy centers, challenges associated with commercializing the company's proton solutions business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges related to entering into new business lines; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The information contained in this document is provided as of the date of its publication and is subject to change without notice. Ms. Kennedy served as President, Proton Solutions & Growth Office at Varian Medical Systems ("Varian") from 2018 until December 31, 2021 when she retired.

"title": "Varian Reports Results for Fourth Quarter and Full Fiscal Year 2019; Appoints New President of Interventional Oncology Solutions and New Chief Financial Officer", Our fiscal year 2020 guidance considers the recently announced tariff exclusions from both China and the United States Trade Representative. Non-GAAP earnings per diluted share from continuing operations for the second through fourth quarters of the fiscal year are expected to be in the range of $2.94 to $3.06. Prior to joining Varian, Bruff held a series of senior international and domestic roles, including business segment CFO, and roles in financial planning, accounting and internal audit at Dell Technologies.

"introText": "",

[citation needed].

Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163investors@varian.com, Press ContactMark PlungyDirector, Public Relations+1 (650) 424-5630mark.plungy@varian.com.

", (Dollars and shares in millions, except per share amounts), Net cash provided by operating activities, Non-GAAP net earnings attributable to Varian (1), Non-GAAP net earnings per share - diluted (1), Shares used in computing GAAP and non-GAAP net earnings per diluted share. Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables wereremoved, added and changedby Varian Medical Systems Inc. Varian Medical Systems Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes: Given the uncertain impact of COVID-19 and/or other market factors on our business, our cash flow projections for this business could decrease in the future, which could lead to an impairment of goodwill. These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements.

After the state supreme court ruled that a new trial would be necessary because of that technical concern,[36] the case was settled on undisclosed terms.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Riverside Drug Bust 2020, Articles V